Article: https://www.venturesquare.net/963758#translated-en

Artblood, a biotechnology company that produces blood for transfusion, announced on the 4th that it has signed a memorandum of understanding (MOU) with Expression Manufacturing LLC (“Expression”), a manufacturing subsidiary of Expression Therapeutics, for clinical development and large-scale production of in vitro produced blood. Through this agreement, Artblood plans to begin mass production of artificial blood and in vitro produced blood in cooperation with Expression.

(...)

As part of the collaboration, Artblood will provide its unique technology and expertise in red blood cell proliferation, differentiation, purification and quality control analysis, while Expression will be responsible for volume production based on its extensive experience in cell therapy manufacturing in compliance with cGMP requirements. The two companies will also pursue joint intellectual property development and global commercialization strategies targeting the artificial blood market.

“This MOU is a significant milestone that opens a new era in transfusion medicine,” said Baek Eun-jung, CEO of Artblood. “Through our collaboration with Expression, we will do our best to accelerate the development of in vitro produced blood and ensure that it is recognized and introduced worldwide.”

“This partnership aligns with our mission to develop next-generation cell and gene therapies,” said Mohan Rao, CEO of Expression Therapeutics. “Expression Manufacturing has a proven track record of producing complex biopharmaceuticals under rigorous regulatory standards, and we are excited to add our expertise to Artblood’s BioBlood program.” He added that the advancement of in vitro blood production technology will contribute to global healthcare needs.

강진희

Source : VENTURE SQUARE(https://www.venturesquare.net/)